Sinopharm Group (HKG:1099) reported 5.31 billion yuan in attributable profit for the nine months ended Sept. 30, rising from 5.28 billion yuan a year earlier, according to a Hong Kong bourse filing Monday.
Earnings per share were 1.70 yuan, compared with 1.69 in the prior year.
Operating revenue fell to 431.48 billion yuan from 442.42 billion last year, figures showed.